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NTs (neurotrophins) are a family of protein ligands, includ-ing NGF (nerve growth factor), BDNF (brain-derived 
neurotrophic factor), NT-3, and NT-4/5. They act on 2 distinct 
receptor types: the TRK (tropomyosin kinase receptors) A, B, 
and C and the neurotrophin receptor p75NTR, which belongs to 
the TNF-α (tumor necrosis factor) receptor family1 (Figure IA 
in the online-only Data Supplement). NTs were initially iden-
tified as regulators of neuronal prosurvival and regenerative 
actions. We and others have later shown that NTs also pro-
mote cardiovascular development, protection, and regenera-
tion, including by stimulating postischemic angiogenesis 
(reviewed in Caporali and Emanueli1). Additional evidence 
suggests a regulatory role of BDNF on stem cells (SCs) and 
vascular progenitor cells.2–8 In fact, pluripotent SCs have been 
reported to express TRKB and TRKC and to secrete BDNF, 
NT‐3, and NT‐4/5, which serve as autocrine prosurvival 
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Objective—The NTs (neurotrophins), BDNF (brain-derived neurotrophic factor) and NT-3 promote vascular development 
and angiogenesis. This study investigated the contribution of endogenous NTs in embryonic stem cell (ESC) vascular 
differentiation and the potential of exogenous BDNF to improve the process of ESC differentiation to endothelial cells (ECs).
Approach and Results—Mouse ESCs were differentiated into vascular cells using a 2-dimensional embryoid body (EB) model. 
Supplementation of either BDNF or NT-3 increased EC progenitors’ abundance at day 7 and enlarged the peripheral vascular 
plexus with ECs and SM22α+ (smooth muscle 22 alpha-positive) smooth muscle cells by day 13. Conversely, inhibition 
of either BDNF or NT-3 receptor signaling reduced ECs, without affecting smooth muscle cells spread. This suggests 
that during vascular development, endogenous NTs are especially relevant for endothelial differentiation. At mechanistic 
level, we have identified that BDNF-driven ESC-endothelial differentiation is mediated by a pathway encompassing the 
transcriptional repressor EZH2 (enhancer of zeste homolog 2), microRNA-214 (miR-214), and eNOS (endothelial nitric 
oxide synthase). It was known that eNOS, which is needed for endothelial differentiation, can be transcriptionally repressed 
by EZH2. In turn, miR-214 targets EZH2 for inhibition. We newly found that in ESC-ECs, BDNF increases miR-214 
expression, reduces EZH2 occupancy of the eNOS promoter, and increases eNOS expression. Moreover, we found that 
NRP-1 (neuropilin 1), KDR (kinase insert domain receptor), and pCas130 (p130 Crk-associated substrate kinase), which 
reportedly induce definitive endothelial differentiation of pluripotent cells, were increased in BDNF-conditioned ESC-EC. 
Mechanistically, miR-214 mediated the BDNF-induced expressional changes, contributing to BDNF-driven endothelial 
differentiation. Finally, BDNF-conditioned ESC-ECs promoted angiogenesis in vitro and in vivo.
Conclusions—BDNF promotes ESC-endothelial differentiation acting via miR-214.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38:2117-2125. 
DOI: 10.1161/ATVBAHA.118.311400.)
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factors.2 Moreover, BDNF reportedly induced the endothelial 
differentiation of human fetal CD133+ SCs and mesenchymal 
SCs.3,9Studies on global knockout mouse models revealed the 
importance of NT-3 and BDNF for vascular development.10,11 
In particular, BDNF deficiency reduced endothelial cell-cell 
contact in the mouse embryonic heart, leading to intraventric-
ular wall hemorrhage.11 Similarly, mice with gene knockout 
for the BDNF receptor TRKB showed a decreased blood ves-
sel density and increased number of TUNEL-positive apop-
totic endothelial cells (EC).12 NT-3 knockout mice developed 
abnormalities of the great vessels.10,13,14 Taken together the 
NT family have important roles in vascular morphology and 
function.
Research in regenerative medicine is currently focus-
sing extensively on tissue engineering. These applications 
require large numbers of well-characterised cells for larger 
scale fabrication of biomaterials.15 Simultaneously, the inter-
est in the use of SCs for disease modeling and drug testing in 
the dish is growing. For the aforementioned areas of trans-
lational research, the use of naive or genetically engineered 
embryonic stem cell (ESC) lines offers clear advantages in 
comparisons to patient-derived adult progenitor cells, which 
had limited plasticity and capacity of growth and differentia-
tion, epigenetic defects, and difficulties in harvesting from 
patients.15,16 Within vascular biomedicine the protocol for 
production of ESC-derived ECs are still being optimized 
to meet the criteria of first-in-man trials and clinical trans-
lation.17–20 The precise growth factor and cytokine cocktail 
required for optimal differentiation of cultured ESCs into 
ECs remain to be accurately determined, in part, because the 
mediators of the endothelial differentiation process are only 
partially explored. Therefore, further research is needed to 
understand the mechanisms required for generation of robust 
and highly angiogenic ECs.
PcG (Polycomb group) proteins play a key role in ESC 
commitment and differentiation by repressing transcription 
of developmental regulators.21–25 EZH2 (enhancer of zeste 
homolog 2), the PcG catalytic subunit, is part of the PRC2 
(polycomb repressive complex 2) and mediates the trimeth-
ylation of histone H3 on lysine 27 (H3K27m3) in target 
gene promoters leading to epigenetic silencing.26 EZH2 was 
previously suggested to regulate both maintenance of pluri-
potency and vascular commitment4,27–31 and PRC2 has been 
shown to silence cohorts of developmental genes in murine 
and human ESCs.21,32–34 We have previously reported that 
EZH2 represses eNOS (endothelial nitric oxide synthase) 
transcription in mature ECs.4 NO is essential for the meso-
dermic differentiation of mouse ESC (mESC) and to pro-
duce proangiogenic mESC-derived ECs.35 Moreover, mESCs 
respond to increased levels of either intracellular (produced 
by eNOS) or extracellular NO (NO donors) by upregulating 
expression of vascular lineage–associated genes, including 
CD31, VEGF (vascular endothelial growth factor) receptor 
2 (VEGF-R2, also known as Flk1 [fetal liver kinase 1 recep-
tor] in mouse and KDR [kinase insert domain receptor] in 
human), smooth muscle actin, and the α-sarcomeric actin 
(reviewed in Wu and Zhang36). MicroRNAs (miRs) have 
been shown to contribute to EZH2 regulation.31,37 miRs are a 
class of endogenous small noncoding RNAs that control post-
transcriptional gene expression, thus influencing vascular cell 
growth, differentiation, and function38–41 and are expressed in 
ESCs42 and vascular cells.43 EZH2 has been shown to inhibit 
the transcription of miR-214 during skeletal muscle cell dif-
ferentiation from ESC44,45 and as a feedback mechanism, 
miR-214 inhibits EZH2 at the post-transcriptional level.44 
miR-214 has been shown to regulate apoptosis, prolifera-
tion, cancer angiogenesis,46,47 skeleton formation,48 and heart 
hypertrophy.37 However, the function of miR-214 in vascular 
differentiation and the possible link between miR-214 and 
EZH2 in the context of ESC-endothelial differentiation have 
not been reported.
An important objective for endothelial differentiation of 
pluripotent SCs is the stability of the differentiation. NRP-1 
(neuropilin 1) is a nontyrosine kinase receptor for VEGF and 
other growth factors or morphogens. In EC, p130(Cas) tyro-
sine phosphorylation is stimulated by VEGF and is dependent 
on the NRP-1 intracellular domain. In fact, NRP-1 silencing 
reduces VEGF-R2 in ECs.49,50 Importantly, NRP-1-mediated 
enhancement of VEGF-R2 signaling through VEGF was 
shown to produce a stable endothelial phenotype with high 
clonal proliferative potential and functional neovasculariza-
tion capacity in vivo.51
Therefore, understanding the transcriptional and post-
transcriptional mechanisms controlling ESC-EC differentia-
tion in response to growth factors might be key to developing 
better ESC-derived approaches to treating vascular diseases. 
Here, we have mechanistically investigated the potential of 
NTs to contribute to ESC differentiation in ECs.
Materials and Methods
The authors declare that all supporting data are available within the 
article (and its online-only Data Supplement files). A comprehensive 
version of the Materials and Methods has been included in the online-
only Data Supplement.
Western Blot
Western blot was performed as previously described.52 Please refer 
Materials and Methods section in the online-only Data Supplement 
for further details.
Nonstandard Abbreviations and Acronyms
BDNF brain-derived neurotrophic factor
EB embryoid body
EC endothelial cell
eNOS endothelial nitric oxide synthase
EZH2 enhancer of zeste homolog 2
mESC mouse embryonic stem cell
miR microRNA
NGF nerve growth factor
NT neurotrophin
PcG polycomb group
PRC2 polycomb Repressive Complex 2
TNF-α tumor necrosis factor α
TRKB/C tropomyosin receptor kinase B/C
VEGF vascular endothelial growth factor
D
ow
nloaded from
 http://ahajournals.org by on October 8, 2018
Descamps et al  BDNF Promotes the Endothelial Differentiation of ESCs  2119
Three-Dimensional–Fibrin Gel Bead Assay
CD31+ cells (ESC-EC) were isolated from differentiated cells using 
MACS (magnetic-activated cell sorting) columns (as described above). 
Passage 3 cells were used for Fibrin gel bead assay and Matrigel plug 
assay (vide infra). Fibrin gel bead assay was performed as previously 
described.53 Please refer Materials and Methods section in the online-
only Data Supplement for further details.
Matrigel Plug Assay
Cells were implanted in Matrigel plugs and injected subcutaneously 
to evaluate their angiogenic effect in vivo as previously described.54,55 
Please refer Materials and Methods section in the online-only Data 
Supplement for further details.
Results
Expression of NT Ligands and Receptors During 
Vascular Embryoid Body Differentiation
We measured expression of the NT system components (Figure 
IA in the online-only Data Supplement). BDNF and NT-3 
(Figure IB in the online-only Data Supplement) together 
with their respective preferential receptors TRKB and TRKC 
(Figure IC in the online-only Data Supplement) appeared 
expressionally regulated during the process of ESC dif-
ferentiation in ECs were, suggesting functional roles for 
both BDNF/TRKB and NT-3/TRKC in the endothelial 
Figure 1. NTs (neurotrophins) promotes endothelial differentiation, and the differentiation process is impaired by NT inhibition. Mouse embryonic stem 
cells were differentiated using an embryoid body (EB) hanging drop protocol. After 4 d, EBs were seeded on 8-well glass culture slides for immunocy-
tochemistry or 12 well-plate for RNA and protein analysis. Cells were treated with BDNF (brain-derived neurotrophic factor) or NT-3 (control: vehicle) 
and without VEGF-A (vascular endothelial growth factor A). A–F, mRNA expression (measured by quantitative real-time polymerase chain reaction) level 
(expressed as relative to vehicle control) of Flk1(fetal liver kinase 1 receptor; n=9; A), Ve-Cadherin (vascular endothelial cadherin; n=8; B) and eNOS 
(endothelial nitric oxide synthase; n=7; C) at day 7 of EB vascular development. D, Quantification of CD31+ area in automatic confocal microscopy 
images (µm2; n=11). E, Quantification of smooth muscle cells spread at day 13 NT (n=11); F and G, Quantification at day 13 of CD31+ (red) vascular 
structures in EB treated with ANA-12 (N-[2-[[(hexahydro-2-oxo-1H-azepin-3-yl)amino]carbonyl]phenyl]-benzo[b]thiophene-2-carboxamide) and TrkCd5 
(tropomyosin kinase receptor C domain 5) inhibitors (n=11). A–E, Comparisons across groups performed both for –VEGF and +VEGF scenarios using 
Kruskal-Wallis test with Dunn test for post hoc testing; the effect of −/+VEGF was tested for each subgroup with Mann-Whitney U test. F–G, Com-
parisons between presence/absence of inhibitors performed with Mann-Whitney U test, *P<0.05, **P<0.01, ***P<0.001 vs control (No VEGF, No NT), 
$P<0.05, $$P<0.01 vs −VEGF+BDNF, ⱡ ⱡ ⱡP<0.001 vs VEGF only (without NTs), ¶¶P<0.01 vs –VEGF+NT-3, ɣP<0.05 vs +VEGF+BDNF. SM22α indicates 
smooth muscle 22 alpha.
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differentiation process. Therefore, we decided to investigate 
those further.
BDNF and NT-3 Promote the Differentiation of ESC 
in Vascular Progenitor Cells
As shown in Figure 1A–1C, either BDNF or NT-3 increased the 
mRNA expression of endothelial markers Flk1, Ve-Cadherin 
(vascular endothelial cadherin), and eNOS in embryoid bod-
ies (EBs). Such changes were similar to the ones observed 
after VEGF-A (used as positive control56) and were not further 
increased by combining NT and VEGF treatment. Flow cytom-
etry analysis confirmed these results, showing that supplemen-
tation of either BDNF or NT-3 increased the number of Flk1+ 
vascular progenitor cells at day 7 (Figure IIA in the online-
only Data Supplement). A similar trend was seen with CD31+ 
EC; however, it was not statistically significant (Figure IIB in 
the online-only Data Supplement). To further study the impact 
of the NTs on vascular differentiation, we analyzed the EBs 
at day 13 of differentiation using automatic confocal micros-
copy mosaic acquisition (Figure IVA and IVB in the online-
only Data Supplement). As shown in Figure 1D and 1E, under 
basal culture conditions, EBs developed a peripheral vascular 
plexus composed of CD31+ and SM22α+ (smooth muscle pro-
tein 22-alpha positive) vascular structures. Exogenous BDNF 
and NT-3 were equally powerful as VEGF to improve the for-
mation of an organized vascular structure composed of mural 
cells surrounding endothelial tubes. Moreover, endogenous 
NTs appeared important for the native vascular development 
process. In fact, as shown in Figure 1F and 1G and Figure 
IVC and IVD in the online-only Data Supplement, inhibition 
of endogenous NT/receptor signaling by blocking the function 
of either TRKB (via a small non peptidic compound ANA-12 
(N-[2-[[(hexahydro-2-oxo-1H-azepin-3-yl)amino]carbonyl]
phenyl]-benzo[b]thiophene-2-carboxamide), 25 mmol/L) or 
TRKC (via soluble TrkC receptor domain TrkCd5 neutralizing 
NT-3, 2µg/mL) led to the formation of a less structured endo-
thelial plexus, with the loss of 38±9% or 28±8% of CD31+ 
cells, respectively. However, the inhibitors did not affect the 
smooth muscle cells expansion (Figure V in the online-only 
Data Supplement). Therefore, we restricted our research focus 
to investigate the impact of NTs on endothelial differentiation.
BDNF Promotes Endothelial Differentiation 
Generating Functional ECs
Based on the expressional trends of the NT family compo-
nents observed during mESC-EC differentiation (Figure I in 
the online-only Data Supplement), we decided to focus on 
BDNF treatment to investigate how NTs impact on the proan-
giogenic capacity of the mESC-derived ECs derived from the 
differentiation process. To this aim, CD31+ cells were sorted 
from EBs at day 10 and plated onto 0.1% gelatin in a differ-
entiation medium supplemented or not with VEGF and BDNF 
(Figure III in the online-only Data Supplement). The CD31+ 
EC progenitors were cultured for up to 6 passages. Similar to 
differentiated ECs, mESC-derived CD31+ cells were able to 
uptake acetylated-LDL (low-density lipoprotein; Figure 2A), 
showed typical endothelial cobblestone morphology, and 
expressed the CD31 endothelial marker(Figure 2B) and were 
capable of forming vascular tube-like structures in a 2-dimen-
sional Matrigel assay (Figure 2C). Untreated ESC-CD31+ 
cells showed a proangiogenic capacity from passage 3 (Figure 
VI in the online-only Data Supplement), whereas both indi-
vidual and combined BDNF or VEGF treatment accelerated 
the proangiogenic capacity of the mESC-derived CD31+ cells 
to passage 2 and 1, respectively (Figure 2C), revealing the 
capacity of BDNF to accelerate endothelial specification and 
improve functionality of derived ECs. By contrast, when com-
pared with VEGF-, BDNF-, or BDNF/VEGF-treated ESC-
derived cells, at passage 3, the cobblestone morphology of 
untreated ESC-CD31+ cells was not homogenous and rather 
composed of a mix of different cells (Figure 2B). Moreover, 
immunostaining highlighted lower expression of endothelial 
markers, such as CD31 and vWF (von Willebrand factor) in 
control cells, revealing that endothelial differentiation was not 
fully achieved in untreated cells (Figure 2B). Importantly, the 
angiogenic capacity of BDNF-induced EC (ESC-EC) was con-
firmed in both the 3-dimensional in vitro angiogenesis model 
and in vivo. In both the fibrin gel bead assay (Figure 2D–2F) 
and the in vivo Matrigel implant assay (Figure 2G and 2H), 
BDNF-induced EC (ESC-EC) showed increased tube length 
and sprout formation when compared with ESC.
BDNF Induces Stable Endothelial Differentiation 
Through miR-214-Dependent Inhibition of EZH2
During ESC-EC differentiation, exogenous BDNF increased 
eNOS mRNA expression (Figure 1C) and decreased EZH2 
expression (Figure 3A). These 2 responses are possibly cor-
related because a CHIP (chromatin immunoprecipitation) for 
EZH2 followed by polymerase chain reaction for the TSS 
(transcription start site) regulatory region of eNOS promoter 
showed that BDNF treatment reduces the promoter (TSS 
−425/−233) occupancy by EZH2 in ESC-ECs (Figure 3B). 
In a different cell type, EZH2 was inhibited by miR-214 at 
post-transcriptional level.44 In line with that, BDNF treatment 
increased miR-214 expression in ESC-ECs (Figure 3C). To 
understand if these events downstream to BDNF are conse-
quential, we successfully inhibited miR-214 expression using 
an anti-miR-214 (Figure 3D). In the presence of BDNF, miR-
214 inhibition increased EZH2 expression (Figure 3E) and 
decreased eNOS expression (Figure 3F), suggesting that miR-
214 mediated the BDNF-induced expressional responses. To 
better understand the stability of endothelial differentiation 
in our system, we next analysed the expression of NRP-1, 
KDR, and p130Cas. BDNF increased the expression of NRP-1 
(Figure 4A), VEGF-R2 (Figure 4B), and p130Cas (Figure 4C 
and 4D) and all these BDNF-induced changes were inhibited 
by anti-miR-214 (Figure 4A–4D).
We finally assessed if BDNF could regulate miR-126, 
which has been described to be important for ESC differentia-
tion to EC and for in vivo vascular development.57 Figure VIII 
in the online-only Data Supplement shows that BDNF does 
not affect miR-126 expression, providing further evidence in 
support of the hypothesis that miR-214 is an important media-
tor of the BDNF action on mESC-EC. Finally, we investi-
gated if miR-214 mediates the action of BDNF in mature EC. 
Interestingly, in human umbilical vein ECs, miR-214 inhi-
bition did not prevent the BDNF-induced increase in eNOS 
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expression (Figure VIIB in the online-only Data Supplement) 
or the BDNF-induced decrease in EZH2 expression (Figure 
VIIC in the online-only Data Supplement). Taken together, 
the data suggest that the BDNF-miR-214 pathway is impor-
tant for endothelial differentiation rather than for postnatal 
angiogenesis. Figure IX in the online-only Data Supplement 
illustrates our proposed model with the cascade of molecular 
events activated by BDNF/TRKB.
Discussion
Our study has provided novel evidence for a role for the NT 
system in stimulating vascular differentiation of ESCs. We 
have shown that BDNF induces endothelial commitment and 
improves the production of ECs, which are proangiogenic in 
vitro and in vivo. We have characterized the molecular changes 
associated with the endothelial differentiation of BDNF-treated 
cells and demonstrated that they are mediated by miR-214. In 
the presence of BDNF, miR-214 expression is increased, thus, 
leading to reduced EZH2 expression. In line with our data, 
miR-214 was already known to target EZH2 mRNA for repres-
sion in a different cell context.44 Expression of eNOS, a well-
characterized example of an endothelial gene, is regulated by 
its chromatin accessibility, and is required for ESC-EC differ-
entiation.35,36 The murine eNOS promoter has been previously 
characterized.36,58 Here, we have shown that BDNF increases 
eNOS in a miR-214-dependent manner. We have also demon-
strated that the presence of BDNF is associated with a reduced 
EZH2 occupancy of the eNOS promoter and ,therefore, removal 
of repressive regulation and an associated increase in eNOS 
expression. Specifically, we have demonstrated that BDNF 
treatment reduced EZH2 occupancy in the eNOS promoter reg-
ulatory sequence between −425/−233 bp upstream to the TSS. 
This region is characterized by the presence of 2 Ets binding 
sites. Ets transcription factors regulate important signaling path-
ways involved in cell differentiation and development in many 
tissues and are critical for driving endothelial gene expression.59
Figure 2. BDNF (brain-derived neurotrophic factor) promotes endothelial differentiation and formation of functional endothelial cells (ECs). To investigate the 
impact of BDNF on the proangiogenic capacity of mouse embryonic stem cell (mESC)-derived ECs, CD31+ cells were sorted from embryoid bodies at day 
10 and plated onto 0.1% gelatin in a differentiation medium supplemented or not with VEGF-A (vascular endothelial growth factor A) and BDNF. A, Sorted 
CD31+ cells were cultured and characterized at passage 3 (n=4).Sorted CD31+ cells were cultured and characterized at passage 3 (n=4). A, Cells present 
cobblestone morphology (scale bar 200 µm) and express CD31 endothelial marker (scale bar 50 µm). They uptake ac-LDL (low-density lipoprotein; n=4; 
scale bar 50 µm) and B, Characterization (cobblestone morphology [A–D; scale bar 200 µm] and immunostaining for CD31/SM22α [smooth muscle 22 alpha; 
E–H; scale bar 50 µm] and CD31/vWF [von Willebrand factor; I–L; scale bar 5.5 µm] marker expression) of EC-ESCs treated with no cytokine (A, E, and I), 
VEGF (D, F, and J), BDNF (C, G, and K) or both growth factors (D, H, and L) at passage 3. C, Representative images of tube length relative to control formed 
on Matrigel (24 h) at passage 3 with different cytokine treatments. (scale bar 500 µm; n=4). D–F, Representative images (D) and quantification of tube length 
(n=4; E) and sprout formation (n=4; F) in cytobeads by pluripotent ESC and ESC-EC (scale bar 50 µm). G–H, Representative images (G) and quantification (H) 
of percentage of isolectin B4 (n=4) comparing ESC and ESC-EC in in vivo Matrigel plug assay. All data are expressed as Mean±SEM. Comparisons between 
groups performed with Mann-Whitney U test. *P<0.05, **P<0.01, ***P<0.001 vs pluripotent ESC.
D
ow
nloaded from
 http://ahajournals.org by on October 8, 2018
2122  Arterioscler Thromb Vasc Biol  September 2018
Previous studies using genetic mouse models reported that 
NTs regulate cardiovascular development10–12,14 (reviewed by 
Caporali and Emanueli13 and Tessarollo1). Despite the impor-
tance of the NT ligand-receptor systems during development 
and in angiogenesis, the NTs implication in the process of 
ESC differentiation to vascular cells was unaddressed. Here, 
we show for the first time that endogenous expression of 
BDNF and NT-3 and their respective receptors increased 
throughout EB differentiation to vascular cells and that 
exogenous addition of BDNF or NT-3 increased the expres-
sion of VEGF-R2, one of the earliest genes expressed during 
endothelial lineage development.60 Ve-Cadherin, a marker of 
mature ECs,61 also increased in differentiating cells treated 
with NTs. The primary vascular plexus in the EB is remod-
eled from day 6 onwards by sprouting angiogenesis. The 
morphology of the vascular plexus formed in 2-dimensional 
EB cultures is dependent on the growth factors present in the 
culture.56 VEGF is the prototypic angiogenic regulator and, 
therefore, is the fundamental factor for vascular develop-
ment and endothelial differentiation,62 and it is commonly 
used in protocols aiming at inducing the endothelial differ-
entiation of pluripotent SCs. VEGF induces the formation of 
a peripheral vascular plexus,56 which we have confirmed in 
this study. However, BDNF or NT-3 also induced the forma-
tion of an organized vascular structure with mural cells sur-
rounding endothelial tubules. The endothelial pattern formed 
after treatment with NTs look different from VEGF induced 
patterning though. VEGF induced a peripheral endothelial 
plexus, whereas BDNF or NT-3 created a more central endo-
thelial structure. Interestingly, combining VEGF with BDNF 
resulted in higher and thicker vascular structures with the 
formation of both central and peripheral endothelial plexus 
suggesting complementarity between VEGF and BDNF, later 
during EB vascular development.63 Inhibition of TRKB or 
TRKC resulted in a less structured endothelial plexus with 
a significant loss of CD31+ cells. NTs increased the smooth 
muscle cell spread, but interestingly, their inhibition did not 
reduce smooth muscle cell spread suggesting other possible 
mechanisms are involved.
BDNF and VEGF share common molecular targets and 
work co-ordinately in some scenarios.64 In 2014, Prasain 
et al51 reported that NRP-1-mediated enhancement of 
VEGF-R2 signaling through VEGF is crucial for VEGF 
mediated endothelial differentiation. Here, we have newly 
demonstrated that BDNF, via miR-214, increases NRP-1, 
VEGF-R2, and p130Cas. This suggests that BDNF might sup-
port the production of cells with a stable arterial endothelial 
phenotype51 and which are highly responsive to hemody-
namic flow.65
We have provided evidence that in mESC-ECs, miR-214 
is increased by BDNF and is fundamental to mediate endo-
thelial differentiation. In this context, miR-214 inhibition pre-
vented the BDNF-induced decrease of EZH2 and increase of 
eNOS in mESC-ECs. However and interestingly, in mature 
Figure 3. BDNF (brain-derived neurotrophic factor) induced functional endothelial differentiation through activation of micro RNA (miR)-214, leading to EZH2 
(enhancer of zeste homolog 2) inhibition and promotion of eNOS (endothelial nitric oxide synthase) transcription. Gene expression was evaluated from undif-
ferentiated or differentiated embryoid bodies (EBs) treated or not with BDNF during vascular EB differentiation. A, EZH2 mRNA expression (n=3) is modulated 
by BDNF during EB vascular differentiation. B, EZH2 occupancy on transcriptional regulatory region (−425/−233 bp from TSS [transcription start site]) of 
the eNOS promoter was reduced by BDNF (n=3). IgG was used as a control in the EZH2-CHIP (chromatin immunoprecipitation). Data were calculated as % 
bound/input. C, miR-214 expression (n=3) is modulated by BDNF during EB vascular differentiation. mRNA expression of miR-214 (D), EZH2 (E), and eNOS 
(F) after treatment of EB with anti-miR-214 50 nM (n=3). A and C, Comparison across subgroups performed with Kruskal-Wallis test with Dunn test for post 
hoc testing; comparison of the effect of BDNF vs control at day 6 performed with Mann-Whitney U test. D–F, Comparisons across groups performed with 
Kruskal-Wallis test with Dunn test for post hoc testing. *P<0.05 vs control of BDNF+scrambled control of anti-miR-214 for D, E, and F), +P<0.05, ++P<0.01, 
+++P<0.001 vs BDNF+scrambled.
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ECs, miR-214 inhibition did not prevent the EZH2 and eNOS 
response to BDNF. We have also investigated if other miRs 
could regulate the action of BDNF in mESC-ECs. In partic-
ular, miR-126, which is enriched in ECs and mediates their 
function during ESC-EC differentiation and in vivo devel-
opmental angiogenesis.57 However, miR-126 expression did 
not seem to be regulated by BDNF. Taken together, the above 
results reinforce the evidence in support of the hypothesis that 
miR-214 is a key mediator of the BDNF actions leading to 
SCs endothelial differentiation.
This basic study has been developed using a murine cell 
line and a well-established EB model of ESC differentiation. 
Future studies are deemed necessary to validate the impor-
tance of BDNF for human ESC-EC-based therapies. Human 
ESC offer obvious translational advantages, especially when 
human ESC-EC are derived and banked under conditions that 
respect the European Tissue and Cells Directives or equiva-
lent extra-European regulatory authorities. For translational 
studies aimed at the production of cells for clinical trials, 
alternative differentiation protocols, ideally compatible with 
automated culturing of adherent cells in bioreactors, might be 
favored to the use of EBs.
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Highlights
• Endogenous neutrotrophins promote endothelial differentiation of embryonic stem cells (ESCs).
• Exogenous BDNF (brain-derived neurotrophic factor) supplementation improves the production of functional endothelial cells from differentiat-
ing ESC.
• BDNF acts via a microRNA-214, which regulates EZH2 (enhancer of zeste homolog 2) and eNOS (endothelial nitric oxide synthase).
• BDNF-conditioned ESC-endothelial cells express higher NRP-1 (neuropilin 1) level, which suggests their stable arterial endothelial phenotype 
and shown functionality in vitro and in vivo.
• Use of BDNF in ESC differentiation protocols might increase the availability of proangiogenic arterial ESC-endothelial cells for therapeutic ap-
plications.
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